Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
| Revenue (Most Recent Fiscal Year) | $385.69M |
| Net Income (Most Recent Fiscal Year) | $-287.22M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 11.92 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 96.83 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -64.37% |
| Net Margin (Trailing 12 Months) | -64.39% |
| Return on Equity (Trailing 12 Months) | -272.80% |
| Return on Assets (Trailing 12 Months) | -36.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.96 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.48 |
| Inventory Turnover (Trailing 12 Months) | 2.39 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.08 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.80 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.77 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 49.24M |
| Free Float | 38.26M |
| Market Capitalization | $5.15B |
| Average Volume (Last 20 Days) | 0.59M |
| Beta (Past 60 Months) | 0.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 81.49% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |